FDA approval of LUNSUMIO™ (mosunetuzumab-axgb) the first-in-class follicular lymphoma (FL) T-cell engaging bispecific antibody. LUNSUMIO, as a single agent, is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Read More. 

Please see the LUNSUMIO full Prescribing Information for additional Important Safety Information, including BOXED Warning.